Results 71 to 80 of about 13,217 (287)

Staging in Gerodontology: A Framework

Gerodontology, EarlyView.
ABSTRACT Introduction Comprehensively, systematically and reproducibly assessing and describing the (oral) health status and care needs of older adults is challenging. We aimed to provide a framework for evaluating and reporting older adults' oral health, capturing general and oral function and disease, as well as oral, systemic and socio‐economic ...
Falk Schwendicke, Gerry McKenna, Murali Srinivasan, Azize Bell, Najla Chebib, Cristiane Da Mata, Helena Dujic, Jennifer Gallagher, Barbara Janssens, Danielle M. Layton, Manabu Kanazawa, Anastassia Kossioni, Sabrina Maniewicz, Koichiro Matsuo, Pedro Molinero Mourelle, Annika Neri, Takahiro Ono, Sungkrit Pojmonpiti, Foteini Spyraki, Kittipit Srisanoi, Saif S. Syed, Sayaka Tada, Georgios Tsakos, Terry R. Walton, W. Murray Thomson, Jean‐Philippe Haesler, Sophie Dartevelle, Frauke Müller   +27 more
wiley   +1 more source

Osteonecrosis of the jaw related to everolimus: a case report

, 2013
Antiresorptive agent-related osteonecrosis of the jaw results in appreciable morbidity in affected patients. Nowadays many physicians prescribe an antiangiogenic agent for the management of malignant metastases.
박형식, 정영수, 김동욱, 정휘동   +3 more
core   +1 more source

Prevention Of Drug-Induced Osteonecrosis Of The Jaw In Cancer Patients

Креативная хирургия и онкология, 2022
The occurrence of drug-induced osteonecrosis of the jaw in cancer patients treated using bone-modifying medications (bisphosphonates and denosumab) is a highly relevant research problem studied by dentists, maxillofacial surgeons, and oncologists ...
E. M. Spevak, D. Yu. Christophorando, V. A. Shutov, A. V. Ermakova   +3 more
doaj   +1 more source

Osteonecrosis of the jaw [PDF]

Australian Prescriber, 2013
I have recently attended a number of meetings with endocrinologists where they consistently state that the incidence of bisphosphonate-related osteonecrosis of the jaw associated with oral bisphosphonate treatment of osteoporosis is about 1 in 100 000. There is obviously a wide variation of opinion.
Graham McNally, Michael McCullough, Alastair Goss   +2 more
openaire   +1 more source

Multiple External Invasive Root Resorption and Calcification in Systemic Sclerosis—Case Report

International Endodontic Journal, EarlyView.
ABSTRACT Aim There are few reports in the literature of multiple external invasive root resorption (EIRR) lesions in patients with systemic sclerosis (SSc), and an association between root resorption and SSc is not well established. We report the only case that comprehensively illustrates—with the combination of histopathology, cone beam computed ...
Jee‐Yun Leung, Geoffrey Heithersay, Richard Logan, Sharon Liberali   +3 more
wiley   +1 more source

The effect of bisphosphonate discontinuation on the incidence of postoperative medication-related osteonecrosis of the jaw after tooth extraction

Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2020
Objectives The discontinuation of bisphosphonate (BP) treatment before tooth extraction may induce medication-related osteonecrosis of the jaw (MRONJ).
Sang-Hoon Kang, Se-Jin Park, Moon-Key Kim   +2 more
semanticscholar   +1 more source

Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?

Case Reports in Dentistry, 2016
Objective. The acronym MRONJ has been created in order to identify “Medication-Related Osteonecrosis of the Jaw,” observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in
Andrea Cassoni, Umberto Romeo, Valentina Terenzi, Marco Della Monaca, Oriana Rajabtork Zadeh, Ingrid Raponi, Maria Teresa Fadda, Antonella Polimeni, Valentino Valentini   +8 more
doaj   +1 more source

Denosumab discontinuation and fracture risk: getting the balance right

Internal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

Endodontic therapy and Medication-related osteonecrosis of the jaw onset: a scoping review and expert opinion-based qualitative meta-synthesis

BMC Oral Health
Introduction Medication-related osteonecrosis of the Jaw (MRONJ) is a serious side effect of bone-modifying agents (BMAs), including bisphosphonates, denosumab, and antiangiogenic drugs.
R. Mauceri, M. Coppini, V. C. A. Caponio, F. Zamparini, C. Prati, G. Campisi   +5 more
doaj   +1 more source

Maxillary osteonecrosis linked to Pembrolizumab therapy: a case report

Journal of Oral Medicine and Oral Surgery
Introduction: Osteonecrosis of the jaw is a serious condition often associated with the use of bone-modifying agents or antiangiogenics. Recent evidence suggests that immune checkpoint inhibitors, including Pembrolizumab, might also contribute to ...
Gosselin-Rousselle Louise, Gaudimier Zoé, Pamelard Pierre-Olivier, Sader Paul, Moizan Hervé   +4 more
doaj   +1 more source